Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.

ABSTRACT: Multinuclear platinum anticancer complexes are a proven option to overcome resistance of established anticancer compounds. Transferring this concept to ruthenium complexes led to the synthesis of dinuclear Ru(II)-arene compounds containing a bis(pyridinone)alkane ligand linker. A pronounced influence of the spacer length on the in vitro anticancer activity was found, which is correlated to the lipophilicity of the complexes. IC(50) values in the same dimension as for established platinum drugs were found in human tumor cell lines. No cross-resistance to oxoplatin, a cisplatin prodrug, was observed for the most active complex in three resistant cell lines; in fact, a 10-fold reversal of sensitivity in two of the oxoplatin-resistant lines was found. (Bio)analytical characterization of the re

SUBMITTER: Mendoza-Ferri MG 

PROVIDER: S-EPMC2819033 | biostudies-literature | 2009 Feb

REPOSITORIES: biostudies-literature